Shares of Zealand Pharma A/S (NASDAQ:ZEAL) popped 10 percent, closing Tuesday at $16.13 for a gain of $1.52, after the first multinational phase III trial of the company's lead candidate, dasiglucagon, met with success in treating severe hypoglycemia.